荷兰生物技术公司提高乙型肝炎疫苗的有效性

StephenW

Dutch Biotech Boosts Hepatitis B Vaccine Effectiveness
Around 15% of people receiving vaccines for hepatitis B fail to produce antibodies that protect them against the infection. These non-responders are often given more injections of the vaccine in an attempt to trigger the immune system, but the effectiveness of this approach varies.

To tackle this problem, the Dutch biotech CyTuVax is developing an enhanced version of the approved hepatitis B vaccine HBVaxPro. In a phase II trial, CyTuVax compared the efficacy of its enhanced treatment with the standard vaccine in 133 people who had previously failed to respond to vaccination.

By the end of the two-month trial, the percentage of people who failed to respond was only 8% in the treatment group compared to 21% in the group given the standard vaccine.

Many vaccines are enhanced with adjuvant treatments such as aluminium to increase the immune response. To make the vaccine even more effective, CyTuVax’s adjuvant includes clumps of immune proteins called cytokines along with the vaccine. These clumps release cytokines slowly over time, stimulating the immune system to react against the vaccine.

CyTuVax is also using the same technology to develop a therapeutic vaccine to treat pancreatic cancer. Co-developed with the research institutions MUMC Maastricht and the UniKlinik Aachen, the treatment is meant to accompany surgery, and is personalized to the patient by targeting antigens expressed by the patient’s tumor.

StephenW

荷兰生物技术公司提高乙型肝炎疫苗的有效性
接受乙型肝炎疫苗接种的人中约有15％未能产生保护他们免受感染的抗体。这些无反应者通常会接种疫苗以试图触发免疫系统，但这种方法的有效性各不相同。

为了解决这个问题，荷兰生物技术公司CyTuVax正在开发一种经批准的乙型肝炎疫苗HBVaxPro的增强版本。在一项II期试验中，CyTuVax比较了其先前未接种疫苗的133名患者的强化治疗与标准疫苗的疗效。

在为期两个月的试验结束时，治疗组中未做出反应的人的比例仅为8％，而接种标准疫苗组的比例为21％。

许多疫苗通过辅助治疗如铝增强，以增加免疫反应。为了使疫苗更有效，CyTuVax的佐剂包括称为细胞因子的免疫蛋白团块以及疫苗。随着时间的推移，这些团块缓慢释放细胞因子，刺激免疫系统对抗疫苗。

CyTuVax也在使用相同的技术开发治疗胰腺癌的治疗性疫苗。与研究机构MUMC Maastricht和UniKlinik Aachen共同开发，该治疗旨在伴随手术，并通过靶向患者肿瘤表达的抗原对患者进行个性化。

齐欢畅

齐欢畅